Health · Pharma & Biotech · 1 hr ago
Lilly’s Foundayo pill eased sleep apnea in late-stage studies
Eli Lilly’s Foundayo pill helped ease sleep apnea in two late-stage studies.
Sleep apnea causes breathing to stop or become restricted during sleep.
In a one-year trial of patients not using PAP ventilation, Foundayo reduced breathing interruptions by 17.8 per hour, compared with 4.5 per hour for a placebo.
More patients on Foundayo reached remission or mild disease: 28%, versus 13% on placebo.
The results were presented at an American Heart Association meeting and published in JAMA.
Foundayo appeared less effective than Lilly’s injectable Zepbound, though the available details do not give a direct comparison between the treatments.
Eli Lilly said its Foundayo obesity pill reduced obstructive sleep apnea severity in two late-stage studies.
The studies measured changes in breathing interruptions per hour over 52 weeks.
Lilly plans to seek U.S. approval by the end of 2026 for Foundayo to treat moderate-to-severe sleep apnea in adults with obesity or who are overweight.
The results were presented Monday at the American Heart Association’s annual meeting and published in JAMA, according to STAT.
STAT reported that Foundayo appeared less effective than Lilly’s injectable drug Zepbound.
- Who
- Eli Lilly and participants with obesity and obstructive sleep apnea.
- What
- Lilly reported that its pill Foundayo reduced sleep apnea severity in two late-stage studies.
- When
- The results were reported on Nov. 9, 2026; the studies measured outcomes at 52 weeks.
- Where
- The results were presented at the American Heart Association’s annual meeting. The studies’ locations are not stated.
- Why
- Lilly plans to seek U.S. approval for Foundayo to treat moderate-to-severe sleep apnea in adults with obesity or who are overweight.
This story does not have two clearly opposing sides.
Researchers measured changes in sleep apnea severity among participants in the two studies.
Lilly reported the study results, which were presented at the American Heart Association’s annual meeting and published in JAMA, according to STAT.
Lilly plans to file for U.S. approval of Foundayo for moderate-to-severe sleep apnea in adults with obesity or who are overweight.
- Studies
- Two late-stage studies
- Study duration
- 52 weeks
- Participants without PAP therapy
- 363 in the first study
- Participants on PAP therapy
- 349 in the second study
- Planned filing
- U.S. approval application by the end of 2026
2 sources
What people are saying
Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with OSA.